Skip to main content
Alton Sartor, MD, Oncology, New Orleans, LA, Tulane Medical Center

AltonOliverSartorMD

Oncology New Orleans, LA

Physician

Dr. Sartor is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sartor's full profile

Already have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1987
  • Tulane University
    Tulane UniversityResidency, Internal Medicine, 1983 - 1986
  • Childrens Hospital of Philadelphia
    Childrens Hospital of PhiladelphiaInternship, Transitional Year, 1982 - 1983
  • Tulane University School of Medicine
    Tulane University School of MedicineClass of 1982

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2023 - 2024
  • LA State Medical License
    LA State Medical License 1984 - 2024
  • MA State Medical License
    MA State Medical License 2006 - 2009
  • MD State Medical License
    MD State Medical License 1986 - 1993
  • PA State Medical License
    PA State Medical License 1982 - 1983
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive ... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PRO... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Hospital Affiliations